Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
CRD SUMMARY: This review concluded that patients with osteoporosis treated with teriparatide have a reduced risk of developing back pain up to 30 months after treatment. The manufacturer of teriparatide funded the review, sponsored the included studies and employed three of the authors. Important systematic review methods that help ensure the findings are reliable were not mentioned in the report.
